Physician profile
Arun Kumar
NPI 1477535078
$14,875.21
in general payments reported to CMS, 2019-2025
52 companies · $2,182 in 2025
The $2,182 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,677 · 2020: $1,443 · 2021: $2,099 · 2022: $2,128 · 2023: $2,329 · 2024: $2,018 · 2025: $2,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,528.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,764.25 | 2019-2025 | |
| Biogen, INC. | $1,425.41 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Ucb, INC. | $1,364.12 | 2019-2025 | Nayzilam, Briviact |
| Alexion Pharmaceuticals, INC. | $996.37 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $840.96 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Abbvie INC. | $661.60 | 2019-2025 | |
| Eisai INC. | $648.63 | 2022-2025 | |
| Amgen INC. | $617.41 | 2019-2022 | |
| Lundbeck LLC | $512.30 | 2020-2025 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $502.23 | 2020-2024 | Wakix |
| Neurocrine Biosciences, INC. | $477.50 | 2022-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $433.62 | 2019-2023 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $429.90 | 2019-2021 | |
| Celgene Corporation | $313.85 | 2023-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $297.24 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.